Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Rating) – Jefferies Financial Group cut their FY2022 earnings per share (EPS) estimates for Bayer Aktiengesellschaft in a report issued on Wednesday, May 11th. Jefferies Financial Group analyst C. Counihan now forecasts that the company will post earnings of $1.95 per share for the year, down from their prior estimate of $1.97. Jefferies Financial Group currently has a “Buy” rating on the stock. Jefferies Financial Group also issued estimates for Bayer Aktiengesellschaft’s FY2023 earnings at $2.14 EPS and FY2025 earnings at $2.33 EPS.
Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Rating) last announced its quarterly earnings results on Tuesday, March 1st. The company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.10. The firm had revenue of $12.72 billion for the quarter, compared to analysts’ expectations of $11.68 billion. Bayer Aktiengesellschaft had a net margin of 4.29% and a return on equity of 22.39%.
Shares of BAYRY stock opened at $15.68 on Friday. The firm’s 50 day moving average price is $16.65 and its two-hundred day moving average price is $15.01. Bayer Aktiengesellschaft has a fifty-two week low of $12.45 and a fifty-two week high of $18.45. The company has a quick ratio of 0.72, a current ratio of 1.11 and a debt-to-equity ratio of 1.10. The stock has a market cap of $61.62 billion, a price-to-earnings ratio of 26.58, a price-to-earnings-growth ratio of 2.10 and a beta of 1.11.
The firm also recently announced a dividend, which will be paid on Monday, May 16th. Shareholders of record on Tuesday, May 3rd will be paid a dividend of $0.3693 per share. The ex-dividend date of this dividend is Monday, May 2nd. This represents a yield of 2.26%. Bayer Aktiengesellschaft’s payout ratio is 59.32%.
Bayer Aktiengesellschaft Company Profile (Get Rating)
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
Recommended Stories
- Get a free copy of the StockNews.com research report on Bayer Aktiengesellschaft (BAYRY)
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.